CS263931B1 - Medicament against diarrhoea - Google Patents

Medicament against diarrhoea Download PDF

Info

Publication number: CS263931B1
Authority: CS; Czechoslovakia
Prior art keywords: diarrhea; drug; formula; active substance; medicament
Prior art date: 1987-09-21

Application number

CS876793A

Other languages

Czech (cs)

English (en)

Other versions

CS679387A1 (en

Inventor

Helena Prof Mudr Drsc Raskova

Viktor Mudr Drsc Clen Ko Bauer

Zdenka Mvdr Csc Urbanova

Ludek Doc Rndr Drsc Benes

Svorad Mudr Csc Stolc

Valeria Rndr Phmr Dittertova

Anna Rndr Phmr Csc Babulova

Original Assignee

Helena Prof Mudr Drsc Raskova

Viktor Mudr Drsc Clen Ko Bauer

Zdenka Mvdr Csc Urbanova

Benes Ludek

Svorad Mudr Csc Stolc

Valeria Rndr Phmr Dittertova

Anna Rndr Phmr Csc Babulova

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-21

Filing date

1987-09-21

Publication date

1989-05-12

1987-09-21 Application filed by Helena Prof Mudr Drsc Raskova, Viktor Mudr Drsc Clen Ko Bauer, Zdenka Mvdr Csc Urbanova, Benes Ludek, Svorad Mudr Csc Stolc, Valeria Rndr Phmr Dittertova, Anna Rndr Phmr Csc Babulova filed Critical Helena Prof Mudr Drsc Raskova

1987-09-21 Priority to CS876793A priority Critical patent/CS263931B1/cs

1988-07-19 Priority to EP88306578A priority patent/EP0309077A3/en

1988-09-16 Publication of CS679387A1 publication Critical patent/CS679387A1/cs

1988-09-21 Priority to US07/247,135 priority patent/US4975450A/en

1988-09-21 Priority to JP63235101A priority patent/JPH01156917A/ja

1988-09-21 Priority to DK524888A priority patent/DK524888A/da

1989-05-12 Publication of CS263931B1 publication Critical patent/CS263931B1/cs

Links

239000003814 drug Substances 0.000 title claims abstract description 23
206010012735 Diarrhoea Diseases 0.000 title claims description 21
150000003839 salts Chemical class 0.000 claims abstract description 4
239000002253 acid Substances 0.000 claims abstract description 3
150000007513 acids Chemical class 0.000 claims abstract description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
FYDDBMAYZHZQLV-UHFFFAOYSA-N pentoxy(phenyl)carbamic acid Chemical compound CCCCCON(C(O)=O)C1=CC=CC=C1 FYDDBMAYZHZQLV-UHFFFAOYSA-N 0.000 claims 1
GCFAUZGWPDYAJN-UHFFFAOYSA-N cyclohexyl 3-phenylprop-2-enoate Chemical compound C=1C=CC=CC=1C=CC(=O)OC1CCCCC1 GCFAUZGWPDYAJN-UHFFFAOYSA-N 0.000 abstract description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
238000011282 treatment Methods 0.000 abstract description 2
201000010099 disease Diseases 0.000 abstract 1
229940079593 drug Drugs 0.000 description 15
230000000694 effects Effects 0.000 description 14
239000013543 active substance Substances 0.000 description 12
241001465754 Metazoa Species 0.000 description 9
150000001875 compounds Chemical class 0.000 description 7
239000004480 active ingredient Substances 0.000 description 6
230000001142 anti-diarrhea Effects 0.000 description 6
239000002775 capsule Substances 0.000 description 6
241000700159 Rattus Species 0.000 description 5
239000000812 cholinergic antagonist Substances 0.000 description 5
230000002048 spasmolytic effect Effects 0.000 description 5
229930003347 Atropine Natural products 0.000 description 4
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
230000003444 anaesthetic effect Effects 0.000 description 4
230000000767 anti-ulcer Effects 0.000 description 4
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 4
229960000396 atropine Drugs 0.000 description 4
244000309466 calf Species 0.000 description 4
239000008101 lactose Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
210000000813 small intestine Anatomy 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 3
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
244000005700 microbiome Species 0.000 description 3
230000035772 mutation Effects 0.000 description 3
235000002639 sodium chloride Nutrition 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000003826 tablet Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
208000010444 Acidosis Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102000005157 Somatostatin Human genes 0.000 description 2
108010056088 Somatostatin Proteins 0.000 description 2
230000007950 acidosis Effects 0.000 description 2
208000026545 acidosis disease Diseases 0.000 description 2
230000007059 acute toxicity Effects 0.000 description 2
231100000403 acute toxicity Toxicity 0.000 description 2
102000030621 adenylate cyclase Human genes 0.000 description 2
108060000200 adenylate cyclase Proteins 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960002896 clonidine Drugs 0.000 description 2
230000001120 cytoprotective effect Effects 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
210000003754 fetus Anatomy 0.000 description 2
239000012530 fluid Substances 0.000 description 2
210000003736 gastrointestinal content Anatomy 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
238000009155 rehydration therapy Methods 0.000 description 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
229960000553 somatostatin Drugs 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000255601 Drosophila melanogaster Species 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
206010028400 Mutagenic effect Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000607626 Vibrio cholerae Species 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
229950006790 adenosine phosphate Drugs 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000021053 average weight gain Nutrition 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000007665 chronic toxicity Effects 0.000 description 1
231100000160 chronic toxicity Toxicity 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
229960004192 diphenoxylate Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
231100000351 embryotoxic Toxicity 0.000 description 1
230000001779 embryotoxic effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
HKIGPMUNBXIAHY-UHFFFAOYSA-N ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate;(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrochloride Chemical compound Cl.OS(O)(=O)=O.CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1.C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HKIGPMUNBXIAHY-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
231100000001 growth retardation Toxicity 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
RRHJHSBDJDZUGL-UHFFFAOYSA-N lidamidine Chemical compound CN=C(N)NC(=O)NC1=C(C)C=CC=C1C RRHJHSBDJDZUGL-UHFFFAOYSA-N 0.000 description 1
229960005045 lidamidine Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
230000009061 membrane transport Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
231100000243 mutagenic effect Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000001151 other effect Effects 0.000 description 1
210000003254 palate Anatomy 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
231100001055 skeletal defect Toxicity 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000007666 subchronic toxicity Effects 0.000 description 1
231100000195 subchronic toxicity Toxicity 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
230000003192 teratological effect Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000007723 transport mechanism Effects 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229940118696 vibrio cholerae Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CS876793A 1987-09-21 1987-09-21 Medicament against diarrhoea CS263931B1 (en)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
CS876793A CS263931B1 (en)	1987-09-21	1987-09-21	Medicament against diarrhoea
EP88306578A EP0309077A3 (en)	1987-09-21	1988-07-19	Antidiarrhoeal therapeutic agent
US07/247,135 US4975450A (en)	1987-09-21	1988-09-21	Antidiarrheal
JP63235101A JPH01156917A (ja)	1987-09-21	1988-09-21	下痢止め薬
DK524888A DK524888A (da)	1987-09-21	1988-09-21	Middel mod diarre

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CS876793A CS263931B1 (en)	1987-09-21	1987-09-21	Medicament against diarrhoea

Publications (2)

Publication Number	Publication Date
CS679387A1 CS679387A1 (en)	1988-09-16
CS263931B1 true CS263931B1 (en)	1989-05-12

Family

ID=5415782

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS876793A CS263931B1 (en)	1987-09-21	1987-09-21	Medicament against diarrhoea

Country Status (5)

Country	Link
US (1)	US4975450A (da)
EP (1)	EP0309077A3 (da)
JP (1)	JPH01156917A (da)
CS (1)	CS263931B1 (da)
DK (1)	DK524888A (da)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4647562A (en) *	1985-02-20	1987-03-03	United Pharmaceuticals, Inc.	Anti-spasmodic agents having three branch chains
US4721722A (en) *	1985-07-12	1988-01-26	United Pharmaceuticals, Inc.	Anti-spasmodic agents containing quaternary nitrogen

1987
- 1987-09-21 CS CS876793A patent/CS263931B1/cs unknown
1988
- 1988-07-19 EP EP88306578A patent/EP0309077A3/en not_active Ceased
- 1988-09-21 JP JP63235101A patent/JPH01156917A/ja active Pending
- 1988-09-21 US US07/247,135 patent/US4975450A/en not_active Expired - Fee Related
- 1988-09-21 DK DK524888A patent/DK524888A/da not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0309077A2 (en)	1989-03-29
EP0309077A3 (en)	1990-03-21
CS679387A1 (en)	1988-09-16
DK524888D0 (da)	1988-09-21
JPH01156917A (ja)	1989-06-20
US4975450A (en)	1990-12-04
DK524888A (da)	1989-03-22

Publication	Publication Date	Title
US4289751A (en)	1981-09-15	Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
ES2335067T3 (es)	2010-03-18	Uso de duloxetina en el tratamiento de la fibromialgia.
US7834056B2 (en)	2010-11-16	Pharmaceutical composition for gout
PT100279B (pt)	1999-06-30	Utilizacao de difenilbutilpiperazinocarboxamidas na presenca de composicoes farmaceuticas para o tratmento de perturbacoes provocadas por abuso de drogas em pacientes viciados e processo de tratamento que as emprega
US4847281A (en)	1989-07-11	Method of medical treatment of addiction
McAllister et al.	1992	Sulphide-induced polioencephalomalacia in lambs
KR20200074154A (ko)	2020-06-24	취약 x 증후군, 엔젤만 증후군 또는 렛 증후군을 포함하는 발달 장애의 경감 또는 치료를 위한 카바메이트 화합물의 용도
US5741807A (en)	1998-04-21	Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas
CS263931B1 (en)	1989-05-12	Medicament against diarrhoea
CN108295068A (zh)	2018-07-20	小檗碱的医药用途
Hudson et al.	1975	Prostaglandin E in cholera toxin-induced intestinal secretion: Lack of an intermediary role
Wintrobe et al.	1942	The prevention of sensory neuron degeneration in the pig, with special reference to the role of various liver fractions
Polin et al.	1962	Amprolium: V. Studies on Thiamine Deficiency in Laying Chickens and Their Eggs
US4285972A (en)	1981-08-25	Method of treating scours
US3592890A (en)	1971-07-13	Method of combating atrophic rhinitis
Anjum et al.	1998	Use of second generation quinolones in Poultry
Boyer et al.	1985	Lead induction of crop dysfunction in pigeons through a direct action on neural or smooth muscle components of crop tissue.
JP2004059579A (ja)	2004-02-26	鎮痛剤組成物
JPH0232020A (ja)	1990-02-01	モルフィン鎮痛治療における耐性発現の抑制方法および薬剤
CN120093733A (zh)	2025-06-06	穿心莲内酯在制备预防和/或治疗苯二氮䓬类药物成瘾的药物中的用途
US4192886A (en)	1980-03-11	Methods for treating gastrointestinal disease
Lehman et al.	1933	Cinchophen Toxicosis: Results of Experimental Subacute and Chronic Cinchophen Poisoning
CN121197142A (zh)	2025-12-26	小白菊内酯在制备预防和/或治疗尼古丁成瘾药物中的用途
ES3015458T3 (en)	2025-05-05	Blend containing aripiprazole and a carbamate compound for prevention, mitigation, or treatment of schizophrenia
Willard et al.	1984	Gastric complications associated with correction of chronic diaphragmatic hernia in two dogs